Innovita Biological Technology Co. Ltd. A Cash Flow-to-Debt Ratio
Innovita Biological Technology Co. Ltd. A cash flow-to-debt ratio. Innovita Biological Technology Co. Ltd. A (688253) has a Cash Flow-to-Debt Ratio of 0.86x as of December 2025, meaning its operating cash flow of CN¥193.13 Million could theoretically repay 1% of its total liabilities (CN¥223.32 Million) in one year. Check 688253 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Innovita Biological Technology Co. Ltd. A (2020–2025)
Cash flow-to-debt ratio of Innovita Biological Technology Co. Ltd. A from 2020 to 2025. Historical debt coverage capacity for Innovita Biological Technology Co. Ltd. A across 6 annual periods. Check 688253 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Innovita Biological Technology Co. Ltd. A Cash Flow-to-Debt Ratio by Year (2020–2025)
Innovita Biological Technology Co. Ltd. A cash flow-to-debt ratio by year from 2020 to 2025. Year-by-year debt coverage analysis for Innovita Biological Technology Co. Ltd. A. For the full cash flow conversion analysis, see Innovita Biological Technology Co. Ltd. cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.86x | CN¥193.13 Million | CN¥223.32 Million | ▼ -38.0% |
| 2024 | 1.39x | CN¥305.46 Million | CN¥219.07 Million | ▲ +20.0% |
| 2023 | 1.16x | CN¥259.85 Million | CN¥223.65 Million | ▲ +132.7% |
| 2022 | 0.50x | CN¥126.43 Million | CN¥253.24 Million | ▼ -72.0% |
| 2021 | 1.78x | CN¥106.27 Million | CN¥59.70 Million | ▼ -68.3% |
| 2020 | 5.61x | CN¥639.82 Million | CN¥114.08 Million | — |